The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...
Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results